8-K: Cardinal Health Exceeds Expectations, Raises FY24 EPS Guidance and Provides Preliminary FY25 Outlook

Cardinal Health reported a strong third quarter with a 9% revenue increase and raised its fiscal year 2024 non-GAAP EPS guidance while also providing a preliminary outlook for fiscal year 2025.

Summary

• Cardinal Health's revenue for the third quarter of fiscal year 2024 increased by 9% to $54.9 billion compared to $50.5 billion in the same quarter of the previous year.
• GAAP operating earnings were $367 million, while non-GAAP operating earnings rose by 10% to $666 million.
• GAAP diluted EPS was $1.05, and non-GAAP diluted EPS increased by 20% to $2.08.
• The company has raised and narrowed its fiscal year 2024 non-GAAP EPS guidance to a range of $7.30 to $7.40, up from the previous range of $7.20 to $7.35.
• Cardinal Health provided a preliminary fiscal year 2025 non-GAAP EPS guidance of at least $7.50.
• The Pharmaceutical and Specialty Solutions segment saw a 9% revenue increase to $50.7 billion and a 4% profit increase to $580 million.
• The Global Medical Products and Distribution segment experienced a 4% revenue increase to $3.1 billion and a profit increase of $66 million to $20 million.
• The Other segment revenue increased by 14% to $1.2 billion, with a 5% profit increase to $111 million.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, increased non-GAAP earnings, raised guidance, and a positive outlook for the next fiscal year. While there are some negative aspects, such as the GAAP earnings decline and goodwill impairment, the overall tone is optimistic and forward-looking.

Positives

• The company experienced broad-based growth across its segments.
• The Pharmaceutical and Specialty Solutions segment showed solid profit growth.
• The Global Medical Products and Distribution segment is showing ongoing acceleration.
• The company's non-GAAP EPS guidance for fiscal year 2024 has been raised and narrowed.
• A preliminary non-GAAP EPS guidance for fiscal year 2025 has been provided, indicating continued growth.
• The company's U.S. Medical Products and Distribution business was recognized for supply chain resiliency.
• Cardinal Health received approval by the Science Based Targets initiative (SBTi) for its near-term science-based greenhouse gas (GHG) emissions reduction targets.

Negatives

• GAAP operating earnings decreased by 36% to $367 million.
• GAAP diluted EPS decreased by 22% to $1.05.
• Net earnings attributable to Cardinal Health, Inc. decreased by 25% to $258 million.
• The company recorded a non-cash, pre-tax goodwill impairment of $90 million related to the Global Medical Products and Distribution segment.

Risks

• The company faces risks from ongoing inflationary pressures.
• There are risks associated with the ongoing review of operations, portfolio, and businesses.
• Competitive pressures in various lines of business could impact performance.
• The company faces risks related to the loss of a significant Pharmaceutical and Specialty Solutions segment customer contract.
• There are ongoing risks associated with the distribution of opioids and related settlements.
• The company is subject to a Department of Justice investigation concerning its anti-diversion program.
• Risks exist related to the manufacture and sourcing of certain products, including those from China.
• The company faces risks associated with the pricing of branded pharmaceuticals.
• There are risks associated with business process initiatives, such as the Global Medical Products and Distribution Improvement Plan.
• The company may not realize the anticipated benefits related to its updated operating and segment reporting structure.
• There are risks associated with the acquisition of Specialty Networks, including the failure to realize anticipated benefits.

Future Outlook

The company has raised its fiscal year 2024 non-GAAP EPS guidance and provided a preliminary non-GAAP EPS guidance for fiscal year 2025, indicating expected continued growth and profitability.

Management Comments

• In Q3, we delivered broad-based growth, including solid profit growth in Pharmaceutical and Specialty Solutions, on top of an exceptionally strong quarter from a year ago, said Jason Hollar, CEO of Cardinal Health.
• We were also pleased to see the ongoing acceleration in GMPD, said Jason Hollar, CEO of Cardinal Health.
• With confidence in our outlook for the year, we are raising and narrowing our FY24 EPS guidance and providing preliminary guidance for FY25 that reflects the strength and resiliency of our company, said Jason Hollar, CEO of Cardinal Health.

Industry Context

This announcement reflects a positive trend in the healthcare distribution industry, with Cardinal Health demonstrating strong performance in both pharmaceutical and medical product segments. The company's focus on supply chain resiliency and strategic acquisitions aligns with broader industry trends.

Comparison to Industry Standards

• Cardinal Health's 9% revenue growth is a strong result compared to some of its peers in the healthcare distribution sector, such as McKesson and AmerisourceBergen, which have also reported solid growth but may not have seen the same level of acceleration in certain segments.
• The 20% increase in non-GAAP diluted EPS is particularly noteworthy, indicating strong operational efficiency and cost management, which is a key focus for companies in this industry.
• The raised and narrowed FY24 EPS guidance and the preliminary FY25 guidance suggest a positive outlook, which is a positive signal for investors compared to companies that may be facing more uncertainty.
• The acquisition of Specialty Networks is a strategic move that aligns with the industry trend of consolidation and expansion into specialized healthcare services, similar to moves made by other large distributors.
• The recognition for supply chain resiliency is a significant achievement, as supply chain disruptions have been a major challenge in the healthcare industry, and this recognition positions Cardinal Health as a leader in this area.

Management Changes

Stakeholder Impact

• Shareholders will likely react positively to the increased guidance and strong financial results.
• Employees may feel more secure due to the company's positive performance and growth outlook.
• Customers may benefit from the company's focus on supply chain resiliency and strategic acquisitions.
• Suppliers may see increased business opportunities due to the company's growth.
• Creditors may view the company as a lower risk due to its improved financial performance.

Next Steps

• Cardinal Health will host a webcast to discuss third-quarter results.
• The company will participate in the Bank of America Securities Health Care Conference on May 14, 2024.
• The company will participate in the Leerink Partners Healthcare Crossroads Conference on May 29, 2024.

Key Dates

Keywords

Cardinal Health, Pharmaceuticals, Medical Products, Distribution, EPS, Revenue, Operating Earnings, Guidance, Specialty Solutions, Supply Chain, Acquisition